NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE: Efficacy and safety results
J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell… - 2016 - Soc Nuclear Med
629 Objectives To evaluate the activity and safety of 177Lu-DOTA0-Tyr3-Octreotate
(Lutathera®) in patients with advanced, progressive, somatostatin-receptor positive midgut …
(Lutathera®) in patients with advanced, progressive, somatostatin-receptor positive midgut …
NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE.
JR Strosberg, EM Wolin, B Chasen, MH Kulke… - 2016 - ascopubs.org
4005 Background: There are limited therapeutic options for patients with advanced midgut
NETs progressing on first-line somatostatin analog therapy. The purpose of this phase III trial …
NETs progressing on first-line somatostatin analog therapy. The purpose of this phase III trial …
NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: efficacy, safety, QoL results and subgroup analysis
J Strosberg, E Wolin, B Chasen, M Kulke… - Endocrine …, 2016 - endocrine-abstracts.org
Background: Currently, there are limited therapeutic options for patients with advanced
midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy …
midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy …
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
4112 Background: As demonstrated in the primary analysis of the phase 3 NETTER-1 trial,
177Lu-DOTATATE significantly prolonged progression-free survival (PFS) versus high-dose …
177Lu-DOTATATE significantly prolonged progression-free survival (PFS) versus high-dose …
NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated …
JR Strosberg, EM Wolin, B Chasen, MH Kulke… - 2016 - ascopubs.org
194 Background: Currently, there are limited therapeutic options for patients with advanced
midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy …
midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy …
[HTML][HTML] Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J Strosberg, G El-Haddad, E Wolin… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …
progression during first-line somatostatin analogue therapy have limited therapeutic options …
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …
Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine …
JR Strosberg, EM Wolin, BA Chasen, MH Kulke… - 2018 - ascopubs.org
4102 Background: Might potential nephrotoxicity be a risk for therapy with 177Lu-Dotatate?
Among patients randomised in the NETTER-1 study, nephrotoxicity and treatment efficacy …
Among patients randomised in the NETTER-1 study, nephrotoxicity and treatment efficacy …
Symptom diaries of patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE
JR Strosberg, R Srirajaskanthan… - Journal of nuclear …, 2021 - Soc Nuclear Med
We report the impact of 177Lu-DOTATATE treatment on abdominal pain, diarrhea, and
flushing, symptoms that patients with advanced midgut neuroendocrine tumors often find …
flushing, symptoms that patients with advanced midgut neuroendocrine tumors often find …
[HTML][HTML] Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER …
Purpose To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP)
elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate. Methods In …
elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate. Methods In …